×
About 59,122 results

ALLMedicine™ Multiple Myeloma Center

Research & Reviews  26,999 results

Venous thromboembolism in patients with multiple myeloma receiving daratumumab-based re...
https://doi.org/10.1080/10428194.2021.1910687
Leukemia & Lymphoma; Wang J, Park C et. al.

Apr 10th, 2021 - It is unknown if daratumumab could affect venous thromboembolism (VTE) risks in patients with multiple myeloma (MM). In this study, individual participant data from three trials comparing daratumumab (DARA) and non-DARA regimens, the CASTOR, PULLO...

Multiple myeloma: when radiography suggests diagnosis.
https://doi.org/10.1136/bcr-2021-241990
BMJ Case Reports; Pires O, Oliveira AA et. al.

Apr 9th, 2021 - Multiple myeloma: when radiography suggests diagnosis.|2021|Pires O,Oliveira AA,Morais J,Regadas MJ,|

Upfront Carfilzomib, Lenalidomide, Dexamethasone with Transplant in Multiple Myeloma Pa...
https://doi.org/10.1182/blood.2021010744
Blood Roussel M, Lauwers-Cances V et. al.

Apr 7th, 2021 - Bortezomib, lenalidomide, dexamethasone plus transplant is a standard of care for eligible Multiple Myeloma patients. As responses can deepen with time, regimens with longer and more potent induction/consolidation phases are needed. In this phase ...

Health-related quality of life in patients with relapsed or refractory multiple myeloma...
https://doi.org/10.1111/bjh.17435
British Journal of Haematology; Plesner T, Dimopoulos MA et. al.

Apr 6th, 2021 - In the phase 3 POLLUX trial, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly improved progression-free survival in patients with relapsed/refractory multiple myeloma (RRMM) compared with lenalidomide and dexamet...

The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma.
https://doi.org/10.1182/bloodadvances.2020002578
Blood Advances; Lipchick BC, Utley A et. al.

Apr 6th, 2021 - Resistance to the proteasome inhibitor bortezomib (BTZ) represents a major obstacle in the treatment of multiple myeloma (MM). The contribution of lipid metabolism in the resistance of MM cells to BTZ is mostly unknown. Here we report that levels ...

see more →

Guidelines  185 results

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and fo...
https://doi.org/10.1016/j.annonc.2020.11.014
Annals of Oncology : Official Journal of the European Soc... Dimopoulos MA, Moreau P et. al.

Feb 7th, 2021 - Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.|2021|Dimopoulos MA,Moreau P,Terpos E,Mateos MV,Zweegman S,|diagnosis,epidemiology,therapy,

KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological mali...
https://doi.org/10.1016/j.kint.2020.07.012
Kidney International; Małyszko J, Bamias A et. al.

Dec 5th, 2020 - The bidirectional relationship between cancer and chronic kidney disease (CKD) is complex. Patients with cancer, particularly those with hematological malignancies such as multiple myeloma and lymphoma, are at increased risk of developing acute ki...

Expert Perspective on ASCO20 Immunotherapy Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200234/full/

Jul 1st, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) has emerged to be a game-changer as shown by this first pivotal phase II trial of CAR T-cell therapy in multiple myeloma (MM). Ide-cel is a first-in-class BCMA-directed CAR T-...

KRd, VRd Equivalency in Multiple Myeloma ‘Reassuring’ to Hematologists
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200219/full/

Jun 23rd, 2020 - Awaited results of the ENDURANCE trial showed equivalency between a regimen of carfilzomib plus lenalidomide and dexamethasone (KRd) and bortezomib, lenalidomide, and dexamethasone (VRd) as an initial therapy for patients with standard- or interme...

see more →

Drugs  257 results see all →

Clinicaltrials.gov  29,267 results

Venous thromboembolism in patients with multiple myeloma receiving daratumumab-based re...
https://doi.org/10.1080/10428194.2021.1910687
Leukemia & Lymphoma; Wang J, Park C et. al.

Apr 10th, 2021 - It is unknown if daratumumab could affect venous thromboembolism (VTE) risks in patients with multiple myeloma (MM). In this study, individual participant data from three trials comparing daratumumab (DARA) and non-DARA regimens, the CASTOR, PULLO...

Multiple myeloma: when radiography suggests diagnosis.
https://doi.org/10.1136/bcr-2021-241990
BMJ Case Reports; Pires O, Oliveira AA et. al.

Apr 9th, 2021 - Multiple myeloma: when radiography suggests diagnosis.|2021|Pires O,Oliveira AA,Morais J,Regadas MJ,|

Upfront Carfilzomib, Lenalidomide, Dexamethasone with Transplant in Multiple Myeloma Pa...
https://doi.org/10.1182/blood.2021010744
Blood Roussel M, Lauwers-Cances V et. al.

Apr 7th, 2021 - Bortezomib, lenalidomide, dexamethasone plus transplant is a standard of care for eligible Multiple Myeloma patients. As responses can deepen with time, regimens with longer and more potent induction/consolidation phases are needed. In this phase ...

Health-related quality of life in patients with relapsed or refractory multiple myeloma...
https://doi.org/10.1111/bjh.17435
British Journal of Haematology; Plesner T, Dimopoulos MA et. al.

Apr 6th, 2021 - In the phase 3 POLLUX trial, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly improved progression-free survival in patients with relapsed/refractory multiple myeloma (RRMM) compared with lenalidomide and dexamet...

The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma.
https://doi.org/10.1182/bloodadvances.2020002578
Blood Advances; Lipchick BC, Utley A et. al.

Apr 6th, 2021 - Resistance to the proteasome inhibitor bortezomib (BTZ) represents a major obstacle in the treatment of multiple myeloma (MM). The contribution of lipid metabolism in the resistance of MM cells to BTZ is mostly unknown. Here we report that levels ...

see more →

News  2,377 results

Multiple Myeloma Clinical Practice Guidelines (EHA/ESMO, 2021)
https://reference.medscape.com/viewarticle/948408

Mar 31st, 2021 - Clinical guidelines on the management of multiple myeloma (MM) were published in February 2021 by the European Hematology Association and the European Society for Medical Oncology in HemaSphere.[1] Watchful waiting is recommended for patients with...

First CAR T-Cell Therapy for Multiple Myeloma: Abecma
https://www.medscape.com/viewarticle/948248

Mar 28th, 2021 - Chimeric antigen receptor (CAR) T-cell therapy, described as a "living drug," is now available for patients with relapsed/refractory multiple myeloma who have been treated with four or more prior lines of therapy. The US Food and Drug Administrati...

'Phenomenal' Results with CAR T-Cells in R/R Multiple Myeloma
https://www.medscape.com/viewarticle/946733

Mar 1st, 2021 - Patients with multiple myeloma that has continued to progress despite many lines of therapy have shown deep and durable responses to a new chimeric antigen receptor (CAR) T-cell therapy, idecabtagene vicleucel (ide-cel, under development by Bristo...

NICE Draft Guidance Approves Lenalidomide as Maintenance Treatment for Multiple Myeloma
https://www.medscape.com/viewarticle/944919

Jan 28th, 2021 - The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending lenalidomide (Revlimid, Bristol-Myers Squibb) as first maintenance treatment after an autologous stem cell transplant for newly diagnosed multip...

PharmaMar Soars 21% After Mouse Data Confirm Drug's Efficacy Against COVID
https://www.medscape.com/viewarticle/944712

Jan 26th, 2021 - MADRID (Reuters) - Shares in Spanish pharmaceutical company PharmaMar spiked over 20% on Tuesday after it cited a paper published in the journal Science that confirmed "potent preclinical efficacy" of its drug Aplidin against COVID-19. A study car...

see more →

Patient Education  37 results see all →